DrugPatentWatch Database Preview
Acadia Pharms Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for ACADIA PHARMS INC, and what generic alternatives to ACADIA PHARMS INC drugs are available?
ACADIA PHARMS INC has two approved drugs.
There are nineteen US patents protecting ACADIA PHARMS INC drugs.
There are one hundred and thirty-three patent family members on ACADIA PHARMS INC drugs in twenty-seven countries.
Summary for Acadia Pharms Inc
International Patents: | 133 |
US Patents: | 19 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 2 |
Drugs and US Patents for Acadia Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | DISCN | Yes | No | 10,028,944 | Start Trial | Start Trial | ||||
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | DISCN | Yes | No | 8,110,574 | Start Trial | Y | Y | Start Trial | ||
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | CAPSULE;ORAL | 210793-001 | Jun 28, 2018 | RX | Yes | Yes | 9,296,694 | Start Trial | Y | Y | Start Trial | ||
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | CAPSULE;ORAL | 210793-001 | Jun 28, 2018 | RX | Yes | Yes | 7,115,634 | Start Trial | Y | Y | Start Trial | ||
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-002 | Jun 28, 2018 | RX | Yes | Yes | 8,618,130 | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acadia Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | CAPSULE;ORAL | 210793-001 | Jun 28, 2018 | 7,858,789 | Start Trial |
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | 8,110,574 | Start Trial |
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | 7,858,789 | Start Trial |
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-002 | Jun 28, 2018 | 8,110,574 | Start Trial |
Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-002 | Jun 28, 2018 | 7,858,789 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Acadia Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2010527371 | Start Trial |
Mexico | PA02008770 | Start Trial |
Australia | 2008254238 | Start Trial |
South Korea | 20070083799 | Start Trial |
Spain | 2530258 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.